首页 > 最新文献

Open Respiratory Medicine Journal最新文献

英文 中文
Performance of Impulse Oscillometry in Identifying Restrictive Lung Defects in a Veteran Cohort. 脉冲振荡测量法在识别退伍军人队列中限制性肺缺陷方面的性能。
Q3 Medicine Pub Date : 2024-07-19 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064304109240611054726
Danielle R Glick, Clayton H Brown, Lan Li, Patricia Gucer, Joanna M Gaitens, Melissa A McDiarmid, Stella E Hines

Background: Impulse oscillometry (IOs) is a technique used to evaluate lung function that uses sound waves imposed over tidal breathing to characterize the airways and lung parenchyma. IOs has been particularly useful in the identification of obstructive lung defects. The present analysis seeks to explore the use of IOs in the identification of restrictive lung physiology among a group of Gulf War I veterans exposed to depleted uranium (DU).

Methods: A total of 36 out of a dynamic 85-veteran cohort attended in-person surveillance visits in 2019 and completed both IOs and PFTs. Performance on IOs was evaluated in a cross-sectional analysis of the group overall and in those identified as having restrictive lung defects defined by either spirometry (FEV1/FVC ≥ LLN and FVC < LLN) or lung volumes (TLC < LLN).

Results: A total of 6 individuals were identified as having restriction (4 based on spirometry alone and an additional 2 by lung volumes). When restriction was present, IOs values of both resistance and reactance were significantly more abnormal.

Conclusion: In the assessment of lung function, IOs may be advantageous over PFTs because it is faster to perform and effort-independent. Although little is known about the utility of IOs in identifying restrictive lung physiology, our results support its use.

背景:脉冲振荡测量法(IOs)是一种用于评估肺功能的技术,它利用声波在潮式呼吸中的强加作用来描述气道和肺实质的特征。IOs 在识别阻塞性肺缺陷方面特别有用。本分析报告旨在探讨 IOs 在一组暴露于贫铀(DU)的第一次海湾战争退伍军人中限制性肺生理学鉴定中的应用:方法:在一个动态的 85 名退伍军人队列中,共有 36 人参加了 2019 年的亲自监测访问,并完成了 IOs 和 PFTs。在对该组总体情况进行横断面分析时,对 IOs 的表现进行了评估,并评估了根据肺活量测定(FEV1/FVC ≥ LLN 和 FVC < LLN)或肺容积测定(TLC < LLN)确定的限制性肺缺陷患者的 IOs 表现:共有 6 人被确定为肺功能受限(其中 4 人仅根据肺活量测定,另外 2 人根据肺活量测定)。当存在肺功能受限时,阻力和反应的 IOs 值明显异常:结论:在肺功能评估中,肺活量检查可能比肺功能检查更有优势,因为肺活量检查操作更快,而且不需要费力气。尽管人们对 IOs 在识别限制性肺生理学方面的效用知之甚少,但我们的研究结果支持使用 IOs。
{"title":"Performance of Impulse Oscillometry in Identifying Restrictive Lung Defects in a Veteran Cohort.","authors":"Danielle R Glick, Clayton H Brown, Lan Li, Patricia Gucer, Joanna M Gaitens, Melissa A McDiarmid, Stella E Hines","doi":"10.2174/0118743064304109240611054726","DOIUrl":"10.2174/0118743064304109240611054726","url":null,"abstract":"<p><strong>Background: </strong>Impulse oscillometry (IOs) is a technique used to evaluate lung function that uses sound waves imposed over tidal breathing to characterize the airways and lung parenchyma. IOs has been particularly useful in the identification of obstructive lung defects. The present analysis seeks to explore the use of IOs in the identification of restrictive lung physiology among a group of Gulf War I veterans exposed to depleted uranium (DU).</p><p><strong>Methods: </strong>A total of 36 out of a dynamic 85-veteran cohort attended in-person surveillance visits in 2019 and completed both IOs and PFTs. Performance on IOs was evaluated in a cross-sectional analysis of the group overall and in those identified as having restrictive lung defects defined by either spirometry (FEV1/FVC ≥ LLN and FVC < LLN) or lung volumes (TLC < LLN).</p><p><strong>Results: </strong>A total of 6 individuals were identified as having restriction (4 based on spirometry alone and an additional 2 by lung volumes). When restriction was present, IOs values of both resistance and reactance were significantly more abnormal.</p><p><strong>Conclusion: </strong>In the assessment of lung function, IOs may be advantageous over PFTs because it is faster to perform and effort-independent. Although little is known about the utility of IOs in identifying restrictive lung physiology, our results support its use.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064304109"},"PeriodicalIF":0.0,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design of Interoperable Electronic Health Record (EHR) Application for Early Detection of Lung Diseases Using a Decision Support System by Expanding Deep Learning Techniques. 通过扩展深度学习技术,设计可互操作的电子健康记录 (EHR) 应用程序,利用决策支持系统早期检测肺部疾病。
Q3 Medicine Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064296470240520075316
Jagadamba G, Shashidhar R, Vinayakumar Ravi, Sahana Mallu, Tahani Jaser Alahmadi

Background: Electronic health records (EHRs) are live, digital patient records that provide a thorough overview of a person's complete health data. Electronic health records (EHRs) provide better healthcare decisions and evidence-based patient treatment and track patients' clinical development. The EHR offers a new range of opportunities for analyzing and contrasting exam findings and other data, creating a proper information management mechanism to boost effectiveness, quick resolutions, and identifications.

Aim: The aim of this studywas to implement an interoperable EHR system to improve the quality of care through the decision support system for the identification of lung cancer in its early stages.

Objective: The main objective of the proposed system was to develop an Android application for maintaining an EHR system and decision support system using deep learning for the early detection of diseases. The second objective was to study the early stages of lung disease to predict/detect it using a decision support system.

Methods: To extract the EHR data of patients, an android application was developed. The android application helped in accumulating the data of each patient. The accumulated data were used to create a decision support system for the early prediction of lung cancer. To train, test, and validate the prediction of lung cancer, a few samples from the ready dataset and a few data from patients were collected. The valid data collection from patients included an age range of 40 to 70, and both male and female patients. In the process of experimentation, a total of 316 images were considered. The testing was done by considering the data set into 80:20 partitions. For the evaluation purpose, a manual classification was done for 3 different diseases, such as large cell carcinoma, adenocarcinoma, and squamous cell carcinoma diseases in lung cancer detection.

Results: The first model was tested for interoperability constraints of EHR with data collection and updations. When it comes to the disease detection system, lung cancer was predicted for large cell carcinoma, adenocarcinoma, and squamous cell carcinoma type by considering 80:20 training and testing ratios. Among the considered 336 images, the prediction of large cell carcinoma was less compared to adenocarcinoma and squamous cell carcinoma. The analysis also showed that large cell carcinoma occurred majorly in males due to smoking and was found as breast cancer in females.

Conclusion: As the challenges are increasing daily in healthcare industries, a secure, interoperable EHR could help patients and doctors access patient data efficiently and effectively using an Android application. Therefore, a decision support system using a deep learning model was attempted and successfully used for disease detection. Early disease detection for lung cancer was ev

背景:电子健康记录(EHR)是实时、数字化的病人记录,可提供一个人完整的健康数据概览。电子健康记录(EHR)可提供更好的医疗决策和循证病人治疗,并跟踪病人的临床发展。电子病历为分析和对比检查结果及其他数据提供了一系列新的机会,创建了一个适当的信息管理机制,以提高效率、快速解决和识别问题。目的:本研究的目的是实施一个可互操作的电子病历系统,通过决策支持系统提高护理质量,以识别早期肺癌:拟议系统的主要目标是开发一个安卓应用程序,用于维护电子病历系统和使用深度学习的决策支持系统,以实现疾病的早期检测。第二个目标是研究肺部疾病的早期阶段,以便利用决策支持系统预测/检测肺部疾病:方法:为了提取患者的电子病历数据,开发了一个安卓应用程序。方法:为了提取患者的电子病历数据,开发了一个安卓应用程序。积累的数据被用来创建一个决策支持系统,用于早期预测肺癌。为了对肺癌预测进行训练、测试和验证,我们从准备好的数据集中收集了一些样本,并从患者那里收集了一些数据。收集到的患者有效数据包括 40 至 70 岁的男性和女性患者。在实验过程中,共考虑了 316 幅图像。测试将数据集按 80:20 的比例分区。为了进行评估,对肺癌检测中的大细胞癌、腺癌和鳞癌等 3 种不同疾病进行了人工分类:第一个模型测试了电子病历与数据收集和更新的互操作性限制。在疾病检测系统方面,通过考虑 80:20 的训练和测试比例,预测了大细胞癌、腺癌和鳞状细胞癌类型的肺癌。在考虑的 336 幅图像中,大细胞癌的预测率低于腺癌和鳞癌。分析还显示,大细胞癌主要发生在吸烟的男性身上,而在女性身上则被发现为乳腺癌:随着医疗保健行业面临的挑战与日俱增,一个安全、可互操作的电子病历可帮助病人和医生使用安卓应用程序高效、有效地访问病人数据。因此,我们尝试了使用深度学习模型的决策支持系统,并将其成功用于疾病检测。对肺癌的早期疾病检测进行了评估,该模型的准确率达到了 93%。在未来的工作中,可以整合电子病历数据,以早期检测各种疾病。
{"title":"Design of Interoperable Electronic Health Record (EHR) Application for Early Detection of Lung Diseases Using a Decision Support System by Expanding Deep Learning Techniques.","authors":"Jagadamba G, Shashidhar R, Vinayakumar Ravi, Sahana Mallu, Tahani Jaser Alahmadi","doi":"10.2174/0118743064296470240520075316","DOIUrl":"10.2174/0118743064296470240520075316","url":null,"abstract":"<p><strong>Background: </strong>Electronic health records (EHRs) are live, digital patient records that provide a thorough overview of a person's complete health data. Electronic health records (EHRs) provide better healthcare decisions and evidence-based patient treatment and track patients' clinical development. The EHR offers a new range of opportunities for analyzing and contrasting exam findings and other data, creating a proper information management mechanism to boost effectiveness, quick resolutions, and identifications.</p><p><strong>Aim: </strong>The aim of this studywas to implement an interoperable EHR system to improve the quality of care through the decision support system for the identification of lung cancer in its early stages.</p><p><strong>Objective: </strong>The main objective of the proposed system was to develop an Android application for maintaining an EHR system and decision support system using deep learning for the early detection of diseases. The second objective was to study the early stages of lung disease to predict/detect it using a decision support system.</p><p><strong>Methods: </strong>To extract the EHR data of patients, an android application was developed. The android application helped in accumulating the data of each patient. The accumulated data were used to create a decision support system for the early prediction of lung cancer. To train, test, and validate the prediction of lung cancer, a few samples from the ready dataset and a few data from patients were collected. The valid data collection from patients included an age range of 40 to 70, and both male and female patients. In the process of experimentation, a total of 316 images were considered. The testing was done by considering the data set into 80:20 partitions. For the evaluation purpose, a manual classification was done for 3 different diseases, such as large cell carcinoma, adenocarcinoma, and squamous cell carcinoma diseases in lung cancer detection.</p><p><strong>Results: </strong>The first model was tested for interoperability constraints of EHR with data collection and updations. When it comes to the disease detection system, lung cancer was predicted for large cell carcinoma, adenocarcinoma, and squamous cell carcinoma type by considering 80:20 training and testing ratios. Among the considered 336 images, the prediction of large cell carcinoma was less compared to adenocarcinoma and squamous cell carcinoma. The analysis also showed that large cell carcinoma occurred majorly in males due to smoking and was found as breast cancer in females.</p><p><strong>Conclusion: </strong>As the challenges are increasing daily in healthcare industries, a secure, interoperable EHR could help patients and doctors access patient data efficiently and effectively using an Android application. Therefore, a decision support system using a deep learning model was attempted and successfully used for disease detection. Early disease detection for lung cancer was ev","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064296470"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Bronchoscopy Assessment in Diagnosing the Histopathology Type of Primary Central Lung Tumors. 诊断原发性中央型肺肿瘤组织病理学类型时的临床和支气管镜评估
Q3 Medicine Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064318977240531100045
Mia Elhidsi, Jamal Zaini, Lisnawati Rachmadi, Asmarinah Asmarinah, Aria Kekalih, Noni Soeroso, Menaldi Rasmin

Background: The location and type of a tumor influence the prognosis of lung cancer. Primary Central Lung Tumors (PCLTs) are correlated with poor prognoses and certain histologic types. This study aimed to present a comprehensive exploration of clinical and bronchoscopic assessments for diagnosing the histopathology types of PCLTs and identified the factors associated with certain histologic types.

Methods: This was an observational cross-sectional study of PCLTs, defined as tumors in direct contact with hilar structures or located within the inner two-thirds of the hemithorax. We gathered demographic and clinical data, as well as data on bronchoscopy assessment and histopathology type. Tumor stage, symptoms of superior vena cava syndrome, and enlargement of lymph nodes in the paratracheal and subcarinal regions were also documented.

Results: Of the 895 patients, 37.87% had primary lung tumors, with 17.76% classified as PCLTs. Notably, PCLT cases exhibited a higher proportion of stage III (28.9% vs. 18.3%; p = 0.03) and Squamous Cell Carcinoma (SCC) histopathology (37.1% vs. 17.2%; p = 0.00) compared with non-PCLT cases. Bronchoscopic findings in PCLTs revealed a predilection for central airway masses (25.2%) and compressive distal airway stenosis (25.2%). Subgroup analysis of 159 PCLT cases identified 37.10% as SCC. Multivariate analysis underscored that intraluminal masses predict central SCC (odds ratio 2.075, 95% confidence interval 1.07-3.99; p = 0.028).

Conclusion: The proportion of stage III, SCC histopathological type, and intraluminal lesions was higher in patients with PCLT than in non-PCLT cases. The presence of intraluminal lesions can predict the histopathological type of SCC in patients with PCLTs.

背景:肿瘤的位置和类型会影响肺癌的预后。原发性中央型肺肿瘤(PCLTs)与不良预后和特定的组织病理学类型相关。本研究旨在全面探讨诊断 PCLT 组织病理学类型的临床和支气管镜评估,并确定与某些组织病理学类型相关的因素:这是一项针对PCLT的横断面观察性研究,PCLT被定义为与肺门结构直接接触或位于半胸腔内三分之二处的肿瘤。我们收集了人口统计学和临床数据,以及支气管镜评估和组织病理学类型的数据。我们还记录了肿瘤分期、上腔静脉综合征症状以及气管旁和心包下淋巴结肿大的情况:结果:在 895 名患者中,37.87% 患有原发性肺肿瘤,其中 17.76% 被归类为 PCLT。值得注意的是,与非 PCLT 病例相比,PCLT 病例中 III 期(28.9% 对 18.3%;P = 0.03)和鳞状细胞癌(SCC)组织病理学比例更高(37.1% 对 17.2%;P = 0.00)。PCLT 患者的支气管镜检查结果显示,中央气道肿块(25.2%)和压迫性远端气道狭窄(25.2%)是首选。对 159 例 PCLT 病例进行的分组分析发现,37.10% 的病例为 SCC。多变量分析强调,腔内肿块可预测中心型 SCC(几率比 2.075,95% 置信区间 1.07-3.99;P = 0.028):结论:与非 PCLT 病例相比,PCLT 患者中 III 期、SCC 组织病理类型和腔内病变的比例更高。管腔内病变的存在可预测 PCLT 患者的 SCC 组织病理类型。
{"title":"Clinical and Bronchoscopy Assessment in Diagnosing the Histopathology Type of Primary Central Lung Tumors.","authors":"Mia Elhidsi, Jamal Zaini, Lisnawati Rachmadi, Asmarinah Asmarinah, Aria Kekalih, Noni Soeroso, Menaldi Rasmin","doi":"10.2174/0118743064318977240531100045","DOIUrl":"10.2174/0118743064318977240531100045","url":null,"abstract":"<p><strong>Background: </strong>The location and type of a tumor influence the prognosis of lung cancer. Primary Central Lung Tumors (PCLTs) are correlated with poor prognoses and certain histologic types. This study aimed to present a comprehensive exploration of clinical and bronchoscopic assessments for diagnosing the histopathology types of PCLTs and identified the factors associated with certain histologic types.</p><p><strong>Methods: </strong>This was an observational cross-sectional study of PCLTs, defined as tumors in direct contact with hilar structures or located within the inner two-thirds of the hemithorax. We gathered demographic and clinical data, as well as data on bronchoscopy assessment and histopathology type. Tumor stage, symptoms of superior vena cava syndrome, and enlargement of lymph nodes in the paratracheal and subcarinal regions were also documented.</p><p><strong>Results: </strong>Of the 895 patients, 37.87% had primary lung tumors, with 17.76% classified as PCLTs. Notably, PCLT cases exhibited a higher proportion of stage III (28.9% <i>vs</i>. 18.3%; <i>p</i> = 0.03) and Squamous Cell Carcinoma (SCC) histopathology (37.1% <i>vs</i>. 17.2%; <i>p</i> = 0.00) compared with non-PCLT cases. Bronchoscopic findings in PCLTs revealed a predilection for central airway masses (25.2%) and compressive distal airway stenosis (25.2%). Subgroup analysis of 159 PCLT cases identified 37.10% as SCC. Multivariate analysis underscored that intraluminal masses predict central SCC (odds ratio 2.075, 95% confidence interval 1.07-3.99; <i>p</i> = 0.028).</p><p><strong>Conclusion: </strong>The proportion of stage III, SCC histopathological type, and intraluminal lesions was higher in patients with PCLT than in non-PCLT cases. The presence of intraluminal lesions can predict the histopathological type of SCC in patients with PCLTs.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064318977"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Cardiac MRI in Pulmonary Hypertension- Is it Still an Underutilized Tool. 心脏磁共振成像在肺动脉高压中的作用--它是否仍是一种未被充分利用的工具?
Q3 Medicine Pub Date : 2024-06-04 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064288565240515115239
Prakash Banjade, Ashish Subedi, Sampada Acharya, Asmita Itani, Munish Sharma, Nadeem Kassam, Shekhar Ghamande, Salim Surani

Pulmonary hypertension (PH) is an intricate medical issue resulting from increased pressure in the pulmonary artery (PA). The current gold standard for diagnosis involves an invasive procedure known as right heart catheterization. Nevertheless, cardiac magnetic resonance imaging (cMRI) offers a non-invasive and valuable alternative for evaluating the function, structure, and blood flow through the pulmonary artery (PA) in both the left ventricle (LV) and right ventricle (RV). Additionally, cMRI can be a good tool for predicting mortality by assessing various hemodynamic parameters. We perceive that cMRI may be an underutilized tool in the evaluation of PH. More discussions might be needed to highlight its utility in patients with PH. This article aims to discuss the potential role of cMRI in evaluating PH based on the review of recent literature.

肺动脉高压(PH)是肺动脉(PA)压力增高导致的一个复杂的医学问题。目前诊断的金标准是进行有创操作,即右心导管检查。然而,心脏磁共振成像(cMRI)为评估左心室(LV)和右心室(RV)肺动脉(PA)的功能、结构和血流提供了一种非侵入性的重要替代方法。此外,cMRI 还是通过评估各种血液动力学参数来预测死亡率的良好工具。我们认为,在 PH 的评估中,cMRI 可能是一种未得到充分利用的工具。可能需要进行更多的讨论,以强调其在 PH 患者中的实用性。本文旨在根据最新文献综述讨论 cMRI 在评估 PH 方面的潜在作用。
{"title":"The Role of Cardiac MRI in Pulmonary Hypertension- Is it Still an Underutilized Tool.","authors":"Prakash Banjade, Ashish Subedi, Sampada Acharya, Asmita Itani, Munish Sharma, Nadeem Kassam, Shekhar Ghamande, Salim Surani","doi":"10.2174/0118743064288565240515115239","DOIUrl":"10.2174/0118743064288565240515115239","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) is an intricate medical issue resulting from increased pressure in the pulmonary artery (PA). The current gold standard for diagnosis involves an invasive procedure known as right heart catheterization. Nevertheless, cardiac magnetic resonance imaging (cMRI) offers a non-invasive and valuable alternative for evaluating the function, structure, and blood flow through the pulmonary artery (PA) in both the left ventricle (LV) and right ventricle (RV). Additionally, cMRI can be a good tool for predicting mortality by assessing various hemodynamic parameters. We perceive that cMRI may be an underutilized tool in the evaluation of PH. More discussions might be needed to highlight its utility in patients with PH. This article aims to discuss the potential role of cMRI in evaluating PH based on the review of recent literature.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064288565"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Pulmonary Hypertension among Sudanese Patients with Sickle Cell Disease. 苏丹镰状细胞病患者肺动脉高压的患病率。
Q3 Medicine Pub Date : 2024-05-21 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064292252240422100911
Yousif Ahmed Elfaki, Ahmed Saadeldin Ibrahim, Tarig Hakim Merghani

Background: Sickle Cell Disease (SCD) is a hereditary condition characterized by aberrant red blood cell morphology, leading to persistent hemolytic anemia. The consequential impact of SCD on the pulmonary vasculature can result in pulmonary hypertension (PHT), a severe complication that detrimentally affects the well-being and survival of individuals with SCD. The prevalence and risk determinants of PHT in SCD patients exhibit variations across diverse geographical regions and populations. This study aims to ascertain the prevalence of PHT among Sudanese SCD patients and identify associated factors.

Methods: A cohort of thirty-one adult sickle cell disease (SCD) patients, as confirmed by hemoglobin electrophoresis, were recruited for participation in this cross-sectional study. Comprehensive data encompassing demographic, clinical, and laboratory parameters were collected. Doppler echocardiography was employed to quantify pulmonary arterial systolic pressure (PASP) and evaluate right ventricular size and function.

Results: Within our cohort, the prevalence of PHT was 29%. Active cigarette smoking demonstrated a significant association with PHT (P=0.042), while hydroxyurea therapy exhibited no noticeable impact on PHT (P=0.612).

Conclusion: Our investigation revealed a PHT prevalence of less than one-third in our SCD patient population, aligning with prior studies. Notably, independent of other factors, cigarette smoking emerged as a distinct risk factor for PHT in SCD patients. This highlights the potential utility of smoking cessation as an intervention to delay the onset of this condition. However, further research is imperative to elucidate the mechanisms through which smoking contributes to PHT development in individuals with SCD.

背景:镰状细胞病(SCD)是一种遗传性疾病,其特点是红细胞形态异常,导致持续性溶血性贫血。SCD 对肺血管的影响可导致肺动脉高压 (PHT),这是一种严重的并发症,会对 SCD 患者的健康和生存造成不利影响。在不同的地理区域和人群中,SCD 患者 PHT 的患病率和风险决定因素存在差异。本研究旨在确定苏丹 SCD 患者 PHT 的患病率,并找出相关因素:这项横断面研究招募了 31 名经血红蛋白电泳确认的成年镰状细胞病(SCD)患者。研究人员收集了包括人口统计学、临床和实验室参数在内的全面数据。多普勒超声心动图用于量化肺动脉收缩压(PASP)和评估右心室大小及功能:结果:在我们的队列中,PHT 的发病率为 29%。主动吸烟与 PHT 有明显关系(P=0.042),而羟基脲治疗对 PHT 没有明显影响(P=0.612):我们的调查显示,在我们的 SCD 患者群体中,PHT 患病率不到三分之一,这与之前的研究结果一致。值得注意的是,与其他因素无关,吸烟是 SCD 患者 PHT 的一个独特风险因素。这凸显了戒烟作为一种干预措施对延缓该疾病发病的潜在作用。然而,要阐明吸烟导致 SCD 患者 PHT 发病的机制,进一步的研究势在必行。
{"title":"Prevalence of Pulmonary Hypertension among Sudanese Patients with Sickle Cell Disease.","authors":"Yousif Ahmed Elfaki, Ahmed Saadeldin Ibrahim, Tarig Hakim Merghani","doi":"10.2174/0118743064292252240422100911","DOIUrl":"10.2174/0118743064292252240422100911","url":null,"abstract":"<p><strong>Background: </strong>Sickle Cell Disease (SCD) is a hereditary condition characterized by aberrant red blood cell morphology, leading to persistent hemolytic anemia. The consequential impact of SCD on the pulmonary vasculature can result in pulmonary hypertension (PHT), a severe complication that detrimentally affects the well-being and survival of individuals with SCD. The prevalence and risk determinants of PHT in SCD patients exhibit variations across diverse geographical regions and populations. This study aims to ascertain the prevalence of PHT among Sudanese SCD patients and identify associated factors.</p><p><strong>Methods: </strong>A cohort of thirty-one adult sickle cell disease (SCD) patients, as confirmed by hemoglobin electrophoresis, were recruited for participation in this cross-sectional study. Comprehensive data encompassing demographic, clinical, and laboratory parameters were collected. Doppler echocardiography was employed to quantify pulmonary arterial systolic pressure (PASP) and evaluate right ventricular size and function.</p><p><strong>Results: </strong>Within our cohort, the prevalence of PHT was 29%. Active cigarette smoking demonstrated a significant association with PHT (P=0.042), while hydroxyurea therapy exhibited no noticeable impact on PHT (P=0.612).</p><p><strong>Conclusion: </strong>Our investigation revealed a PHT prevalence of less than one-third in our SCD patient population, aligning with prior studies. Notably, independent of other factors, cigarette smoking emerged as a distinct risk factor for PHT in SCD patients. This highlights the potential utility of smoking cessation as an intervention to delay the onset of this condition. However, further research is imperative to elucidate the mechanisms through which smoking contributes to PHT development in individuals with SCD.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064292252"},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low Doses of Kretek Cigarette Smoke Altered Rat Lung Histometric, and Overexpression of the p53 Gene. 低剂量的 Kretek 卷烟烟雾改变了大鼠肺组织计量学和 p53 基因的过度表达。
Q3 Medicine Pub Date : 2024-04-26 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064285619240327055359
Edy Parwanto, David Tjahyadi, Sisca Sisca, Husnun Amalia, Nany Hairunisa, Hosea Jaya Edy, Ashaolu Victoria Oladimeji, Noureddine Djebli

Background: The components of kretek cigarettes include tobacco as the main part, clove, and sauce. Filtered kretek cigarettes are kretek cigarettes that have one end filtered. Cigarette smoke contributes to the disruption of the respiratory system, so it is necessary to know the effect of low doses of cigarette smoke on changes in the histometric of the respiratory system, and whether it affects p53 gene expression. This study aims to determine changes in the histometric of the respiratory system and p53 gene expression.

Methods: In this study, we used Sprague-Dawley rats. Group I of rats breathing normal air, were not exposed to filtered kretek cigarette smoke (as a control). Group II of rats, as a treatment group, were exposed to filtered kretek cigarette smoke 1 stick/day for 3 months. The results of lung histometry measurements and p53 gene expression between groups were analyzed using the Independent Sample T-test. The difference between groups is significant if the test results show P < 0.05.

Results: Bronchioles length, width, area, and perimeter in group I were 40.55±1.57 μm, 14.82±0.41 μm, 494.61±5.62 μm2, and 233.87±4.51 μm, respectively. Bronchioles length, width, area, and perimeter in group II were 30.76±0.78 μm, 9.28±0.40 μm, 297.32±2.53 μm2, and 177.84±5.15 μm, respectively. The area and perimeter of respiratory bronchioles in group I were 17.68±0.49 μm2, and 26.60±0.52 μm respectively, while those in group II were 19.28±0.35 μm2, and 29.28±0.35 μm, respectively. Mucus was found in the bronchioles and respiratory bronchioles in group II, however, there was no visible mucus observed in group I. In addition, it was also concluded that exposure to low doses of filtered kretek cigarette smoke, 1 cigarette/day for 3 months, increased the expression of the p53 gene in the lungs of rats.

Conclusion: The size of bronchioles in rats decreased after being exposed to filtered kretek cigarette smoke 1 stick/day for 3 months, while the size of respiratory bronchioles increased. In addition, exposure to filtered kretek cigarette smoke increased the expression of the p53 gene in the rat lungs.

背景:克雷泰香烟的成分包括主要成分烟草、丁香和酱料。过滤嘴克雷泰香烟是一端经过过滤的克雷泰香烟。香烟烟雾会导致呼吸系统紊乱,因此有必要了解低剂量香烟烟雾对呼吸系统组织测量变化的影响,以及是否会影响 p53 基因的表达。本研究旨在确定呼吸系统组织测量和 p53 基因表达的变化:本研究使用 Sprague-Dawley 大鼠。I 组大鼠呼吸正常空气,不接触过滤克雷泰香烟烟雾(作为对照)。II 组大鼠作为治疗组,每天接触 1 支过滤嘴克雷泰香烟烟雾,持续 3 个月。采用独立样本 T 检验分析组间肺组织测量和 p53 基因表达的结果。如果检验结果显示 P < 0.05,则组间差异具有显著性:I组支气管长、宽、面积和周长分别为40.55±1.57 μm、14.82±0.41 μm、494.61±5.62 μm2和233.87±4.51 μm。Ⅱ组支气管长、宽、面积和周长分别为(30.76±0.78)μm、(9.28±0.40)μm、(297.32±2.53)μm2 和(177.84±5.15)μm。I 组呼吸支气管的面积和周长分别为(17.68±0.49)μm2 和(26.60±0.52)μm,II 组分别为(19.28±0.35)μm2 和(29.28±0.35)μm。此外,研究还得出结论,接触低剂量过滤克雷泰香烟烟雾(1 支/天,持续 3 个月)会增加大鼠肺部 p53 基因的表达:结论:在连续 3 个月每天吸 1 支过滤嘴克雷泰香烟后,大鼠支气管的体积减小,而呼吸支气管的体积增大。此外,接触过滤嘴克雷泰香烟烟雾会增加大鼠肺中 p53 基因的表达。
{"title":"Low Doses of Kretek Cigarette Smoke Altered Rat Lung Histometric, and Overexpression of the p53 Gene.","authors":"Edy Parwanto, David Tjahyadi, Sisca Sisca, Husnun Amalia, Nany Hairunisa, Hosea Jaya Edy, Ashaolu Victoria Oladimeji, Noureddine Djebli","doi":"10.2174/0118743064285619240327055359","DOIUrl":"10.2174/0118743064285619240327055359","url":null,"abstract":"<p><strong>Background: </strong>The components of kretek cigarettes include tobacco as the main part, clove, and sauce. Filtered kretek cigarettes are kretek cigarettes that have one end filtered. Cigarette smoke contributes to the disruption of the respiratory system, so it is necessary to know the effect of low doses of cigarette smoke on changes in the histometric of the respiratory system, and whether it affects p53 gene expression. This study aims to determine changes in the histometric of the respiratory system and p53 gene expression.</p><p><strong>Methods: </strong>In this study, we used Sprague-Dawley rats. Group I of rats breathing normal air, were not exposed to filtered kretek cigarette smoke (as a control). Group II of rats, as a treatment group, were exposed to filtered kretek cigarette smoke 1 stick/day for 3 months. The results of lung histometry measurements and p53 gene expression between groups were analyzed using the Independent Sample T-test. The difference between groups is significant if the test results show P < 0.05.</p><p><strong>Results: </strong>Bronchioles length, width, area, and perimeter in group I were 40.55±1.57 μm, 14.82±0.41 μm, 494.61±5.62 μm<sup>2</sup>, and 233.87±4.51 μm, respectively. Bronchioles length, width, area, and perimeter in group II were 30.76±0.78 μm, 9.28±0.40 μm, 297.32±2.53 μm<sup>2</sup>, and 177.84±5.15 μm, respectively. The area and perimeter of respiratory bronchioles in group I were 17.68±0.49 μm<sup>2</sup>, and 26.60±0.52 μm respectively, while those in group II were 19.28±0.35 μm<sup>2</sup>, and 29.28±0.35 μm, respectively. Mucus was found in the bronchioles and respiratory bronchioles in group II, however, there was no visible mucus observed in group I. In addition, it was also concluded that exposure to low doses of filtered kretek cigarette smoke, 1 cigarette/day for 3 months, increased the expression of the p53 gene in the lungs of rats.</p><p><strong>Conclusion: </strong>The size of bronchioles in rats decreased after being exposed to filtered kretek cigarette smoke 1 stick/day for 3 months, while the size of respiratory bronchioles increased. In addition, exposure to filtered kretek cigarette smoke increased the expression of the p53 gene in the rat lungs.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064285619"},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards. 人工智能的脉搏:人工智能在医疗保健领域的应用及其潜在危害》(The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards)。
Q3 Medicine Pub Date : 2024-01-19 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064289936240115105057
Syeda Farheen Zaidi, Asim Shaikh, Salim Surani

In this editorial, we explore the existing utilization of artificial intelligence (AI) within the healthcare industry, examining both its scope and potential harms if implemented and relied upon on a broader scale. Collaboration among corporations, government bodies, policymakers, and medical experts is essential to address potential concerns, ensuring smooth AI integration into healthcare systems.

在这篇社论中,我们探讨了人工智能(AI)在医疗保健行业中的现有应用,研究了其应用范围以及在更大范围内实施和依赖人工智能可能带来的危害。企业、政府机构、政策制定者和医学专家之间的合作对于解决潜在问题、确保人工智能顺利融入医疗系统至关重要。
{"title":"The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards.","authors":"Syeda Farheen Zaidi, Asim Shaikh, Salim Surani","doi":"10.2174/0118743064289936240115105057","DOIUrl":"https://doi.org/10.2174/0118743064289936240115105057","url":null,"abstract":"<p><p>In this editorial, we explore the existing utilization of artificial intelligence (AI) within the healthcare industry, examining both its scope and potential harms if implemented and relied upon on a broader scale. Collaboration among corporations, government bodies, policymakers, and medical experts is essential to address potential concerns, ensuring smooth AI integration into healthcare systems.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064289936"},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed. 慢性阻塞性肺病全球倡议 (GOLD) 2023 指南》已审查。
Q3 Medicine Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064279064231227070344
Munish Sharma, Sushil Joshi, Prakash Banjade, Shekhar A Ghamande, Salim Surani

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report is an essential resource for all clinicians who strive to provide optimal care to patients with chronic obstructive lung disease (COPD). The annual report of GOLD makes few revisions and updates besides including data from the preceding year. At an interval, GOLD comes up with a significant modification in its guidelines, which is generally a major overhaul of the pre-existing guidelines. According to the latest 2023 updates, published in November 2022, there have been significant advancements made in the field of COPD. These include the development of more precise definitions for COPD and its exacerbations, the introduction of a new set of parameters to measure exacerbation severity, and updating the COPD assessment tool. Additionally, revisions have been made to the initial and follow-up treatment guidelines. The report also simplifies the treatment algorithm and sheds light on new findings that suggest the use of pharmacological triple therapy can reduce mortality rates. Furthermore, the report includes discussions on inhaler device selection and adherence to COPD medications. These improvements demonstrate a continued effort to enhance COPD treatment and management. Although there are some areas that could benefit from more detailed guidance and explanation, such as the proper utilization of blood eosinophil counts for treatment decisions, and the establishment of treatment protocols post-hospitalization, the latest modifications to the GOLD recommendations will undoubtedly aid healthcare providers in addressing any gaps in patient care. We aim to highlight key changes in the GOLD 2023 report and present a viewpoint about their potential implications in a real-world clinical scenario.

慢性阻塞性肺病全球倡议(GOLD)报告是所有努力为慢性阻塞性肺病(COPD)患者提供最佳治疗的临床医生的重要资源。GOLD 年度报告除了收录前一年的数据外,很少进行修订和更新。每隔一段时间,GOLD 都会对其指南进行重大修改,通常是对原有指南的一次大修。根据 2022 年 11 月发布的最新 2023 年更新版,慢性阻塞性肺病领域取得了重大进展。其中包括为慢性阻塞性肺病及其加重制定了更精确的定义,引入了一套新的参数来衡量加重的严重程度,并更新了慢性阻塞性肺病评估工具。此外,还对初始和后续治疗指南进行了修订。报告还简化了治疗算法,并阐明了新的研究结果,即使用药物三联疗法可降低死亡率。此外,报告还讨论了吸入器的选择和慢性阻塞性肺病药物治疗的依从性。这些改进表明,人们一直在努力加强慢性阻塞性肺病的治疗和管理。尽管在某些方面还需要更详细的指导和解释,如在治疗决策中正确使用血液嗜酸性粒细胞计数和建立入院后治疗方案,但 GOLD 建议的最新修改无疑将有助于医疗服务提供者弥补患者护理中的不足。我们旨在强调 GOLD 2023 报告中的主要变化,并就其在实际临床场景中的潜在影响发表观点。
{"title":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed.","authors":"Munish Sharma, Sushil Joshi, Prakash Banjade, Shekhar A Ghamande, Salim Surani","doi":"10.2174/0118743064279064231227070344","DOIUrl":"https://doi.org/10.2174/0118743064279064231227070344","url":null,"abstract":"<p><p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report is an essential resource for all clinicians who strive to provide optimal care to patients with chronic obstructive lung disease (COPD). The annual report of GOLD makes few revisions and updates besides including data from the preceding year. At an interval, GOLD comes up with a significant modification in its guidelines, which is generally a major overhaul of the pre-existing guidelines. According to the latest 2023 updates, published in November 2022, there have been significant advancements made in the field of COPD. These include the development of more precise definitions for COPD and its exacerbations, the introduction of a new set of parameters to measure exacerbation severity, and updating the COPD assessment tool. Additionally, revisions have been made to the initial and follow-up treatment guidelines. The report also simplifies the treatment algorithm and sheds light on new findings that suggest the use of pharmacological triple therapy can reduce mortality rates. Furthermore, the report includes discussions on inhaler device selection and adherence to COPD medications. These improvements demonstrate a continued effort to enhance COPD treatment and management. Although there are some areas that could benefit from more detailed guidance and explanation, such as the proper utilization of blood eosinophil counts for treatment decisions, and the establishment of treatment protocols post-hospitalization, the latest modifications to the GOLD recommendations will undoubtedly aid healthcare providers in addressing any gaps in patient care. We aim to highlight key changes in the GOLD 2023 report and present a viewpoint about their potential implications in a real-world clinical scenario.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064279064"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Interleukin-4 Receptor α Chain I50V Gene Variant (rs1805010) and Asthma in Iranian Population: A Case-control Study. 伊朗人口中白细胞介素-4 受体 α 链 I50V 基因变异(rs1805010)与哮喘的关系:一项病例对照研究。
Q3 Medicine Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.2174/0118743064266613231123103523
Masouma Mowahedi, Azam Aramesh, Mozhgan Sorkhi Khouzani, Marjan Sorkhi Khouzani, Saeed Daryanoush, Mohammad Samet, Morteza Samadi

Background: Asthma is one of the respiratory disorders caused by chronic airway inflammation. IL-4 has been identified as one of the participating interleukins in the severity of asthma.

Objective: A case-control study was conducted to determine the association of rs1805010, a single nucleotide polymorphism in the interleukin 4 receptor α chain, with asthma and immunoglobulin E and IL-17A serum levels in Iranian populations.

Methods: ELISA was used to investigate the relationship between three different varieties of SNP I50V and serum IL-17A levels, as well as total IgE levels. Based on GINA criteria, patients were classified into mild, moderate, and severe groups based on the association between SNP I50V, IL-17A, and total IgE. In order to analyze the data, the student-t-test and the one-way ANOVA were used.

Results: The SNP I50V was associated with asthma in a significant way (p = 0.001). IL-17A and total IgE levels were significantly higher in asthmatic patients than in control participants (p 0.05 and p 0.021, respectively), but neither showed any association with SNP I50V in the asthmatic patients.

Conclusion: Asthma patients have a higher prevalence of the I allele, reflecting the significance of Th2 cells. Although total IgE and IL-17A levels increased in both disease subgroups, total IgE level augmentation correlates directly with disease severity, while IL-17A level enhancement does not.

背景:哮喘是由慢性气道炎症引起的呼吸系统疾病之一。IL-4 已被确定为参与哮喘严重程度的白细胞介素之一:目的:通过病例对照研究确定 rs1805010(白细胞介素 4 受体 α 链中的单核苷酸多态性)与伊朗人群哮喘、免疫球蛋白 E 和 IL-17A 血清水平的关系:采用酶联免疫吸附法研究三种不同的 SNP I50V 与血清 IL-17A 水平以及总 IgE 水平之间的关系。根据 GINA 标准,按照 SNP I50V、IL-17A 和总 IgE 之间的关系将患者分为轻度、中度和重度组。数据分析采用了student-t检验和单因素方差分析:结果:SNP I50V与哮喘有显著相关性(p = 0.001)。哮喘患者的 IL-17A 和总 IgE 水平明显高于对照组参与者(分别为 p 0.05 和 p 0.021),但两者均与哮喘患者的 SNP I50V 无关:结论:哮喘患者等位基因 I 的发生率较高,反映了 Th2 细胞的重要性。尽管两个疾病亚组的总 IgE 和 IL-17A 水平都有所升高,但总 IgE 水平的升高与疾病的严重程度直接相关,而 IL-17A 水平的升高与疾病的严重程度无关。
{"title":"Association of Interleukin-4 Receptor α Chain I50V Gene Variant (rs1805010) and Asthma in Iranian Population: A Case-control Study.","authors":"Masouma Mowahedi, Azam Aramesh, Mozhgan Sorkhi Khouzani, Marjan Sorkhi Khouzani, Saeed Daryanoush, Mohammad Samet, Morteza Samadi","doi":"10.2174/0118743064266613231123103523","DOIUrl":"https://doi.org/10.2174/0118743064266613231123103523","url":null,"abstract":"<p><strong>Background: </strong>Asthma is one of the respiratory disorders caused by chronic airway inflammation. IL-4 has been identified as one of the participating interleukins in the severity of asthma.</p><p><strong>Objective: </strong>A case-control study was conducted to determine the association of rs1805010, a single nucleotide polymorphism in the interleukin 4 receptor α chain, with asthma and immunoglobulin E and IL-17A serum levels in Iranian populations.</p><p><strong>Methods: </strong>ELISA was used to investigate the relationship between three different varieties of SNP I50V and serum IL-17A levels, as well as total IgE levels. Based on GINA criteria, patients were classified into mild, moderate, and severe groups based on the association between SNP I50V, IL-17A, and total IgE. In order to analyze the data, the student-t-test and the one-way ANOVA were used.</p><p><strong>Results: </strong>The SNP I50V was associated with asthma in a significant way (p = 0.001). IL-17A and total IgE levels were significantly higher in asthmatic patients than in control participants (p 0.05 and p 0.021, respectively), but neither showed any association with SNP I50V in the asthmatic patients.</p><p><strong>Conclusion: </strong>Asthma patients have a higher prevalence of the I allele, reflecting the significance of Th2 cells. Although total IgE and IL-17A levels increased in both disease subgroups, total IgE level augmentation correlates directly with disease severity, while IL-17A level enhancement does not.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"18 ","pages":"e18743064266613"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates on British Thoracic Society Statement on Pleural Disease and Procedures 2023. 英国胸科学会关于胸膜疾病和 2023 年程序声明的更新。
Q3 Medicine Pub Date : 2023-12-01 eCollection Date: 2023-01-01 DOI: 10.2174/0118743064286775231128104253
Ashish Subedi, Prakash Banjade, Sushil Joshi, Munish Sharma, Salim Surani
{"title":"Updates on British Thoracic Society Statement on Pleural Disease and Procedures 2023.","authors":"Ashish Subedi, Prakash Banjade, Sushil Joshi, Munish Sharma, Salim Surani","doi":"10.2174/0118743064286775231128104253","DOIUrl":"https://doi.org/10.2174/0118743064286775231128104253","url":null,"abstract":"","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e18743064286775"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Open Respiratory Medicine Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1